PharmaShots | Incisive News in 3 Shots

Subscribe Now

Intermediate-Poor-Risk Advanced

Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC

Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-...

January 15, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us